How Telehealth Prescribing Works for Stimulants and Other Controlled Substances

One of the most common questions from adults seeking ADHD treatment is whether a stimulant can actually be prescribed without an in-person visit. The short answer, as of this writing, is yes — but it is worth understanding the rule behind that answer, since it is a temporary federal flexibility rather than a permanent settled policy.

The rule behind the rule

Under the Ryan Haight Act of 2008, prescribing a controlled substance by telemedicine normally requires at least one prior in-person evaluation. Starting in 2020, the DEA and HHS suspended that requirement as a COVID-era flexibility, and that suspension has been extended several times since. The current extension allows Schedule II–V controlled substances — which includes ADHD stimulants — to be prescribed by telemedicine without a prior in-person visit through December 31, 2026, while the agencies finalize a permanent framework.

Because this is a temporary extension rather than permanent law, it is worth confirming current status if you are reading this well after publication. The practice stays current on these requirements and will let you know directly if anything changes that affects your care.

What this means for your evaluation

None of this changes what a responsible stimulant evaluation involves. It still requires a genuine clinical history, a look at cardiovascular risk factors, a check of the prescription monitoring database, and an honest conversation about the diagnosis before any medication is prescribed. Telehealth changes where the visit happens, not the thoroughness of the process behind it.

State rules layer on top of federal ones

Federal telemedicine flexibility is the floor, not the whole picture — states can and do add their own requirements around controlled substance prescribing, including prescription monitoring database checks specific to that state. These requirements are handled as a routine part of every visit, regardless of which state you are being seen in.

What could change

The DEA has signaled it intends to move toward a more structured, permanent framework for telemedicine prescribing of controlled substances, likely with more defined requirements than the current temporary rule. If and when that happens, established patients are typically the least affected, since ongoing care with a documented history carries fewer restrictions than a first-time prescription to someone with no treatment relationship.

Can ADHD medication be prescribed without an in-person visit?

Currently, yes. A federal flexibility allows Schedule II–V controlled substances, including ADHD stimulants, to be prescribed by telemedicine without a prior in-person evaluation, through December 31, 2026, while permanent rules are finalized.

Is this rule permanent?

No. It is a temporary extension of a COVID-era flexibility that has been renewed several times. The DEA is working on a permanent framework, which may include different requirements once finalized.

Does telehealth prescribing skip any safety steps?

No. A genuine evaluation, cardiovascular risk review, and prescription monitoring database check are part of every stimulant prescription, whether the visit happens by video or in person.

What happens if the federal rule changes?

Patients already established in care are generally the least affected by regulatory changes, since the requirements that tighten tend to focus on first-time prescriptions without an existing treatment relationship. The practice will communicate directly with patients if anything changes that affects their care.